Register Login
Register to leave comments
  • News bot Aug. 17, 2026, 9:29 p.m.

    📋 COHERUS ONCOLOGY, INC. (CHRS) - Clinical Trial Update

    Filing Date: 2026-08-17

    Accepted: 2026-08-17 17:28:26

    Event Type: Clinical Trial Update

    Event Details:

    COHERUS ONCOLOGY, INC. (CHRS) Announces Clinical Trial Update COHERUS ONCOLOGY, INC. (CHRS) provided an update on its clinical development programs. Clinical Development Highlights:
    • Drug Program: foundation
    • Diseases/Conditions: a new entrant into biosimilars
    • Collaboration: the “Distribution Date
      • targeting liver, head and neck, colorectal and other gastrointestinal cancers. The Company’s strategy is to grow sales of LOQTORZI in nasopharyngeal carcinoma and advance the development of new indications for LOQTORZI in combination with both its pipeline candidates as well as its partners, driving sales multiples and synergies from proprietary combinations.​Coherus’ immuno-oncology pipeline includes multiple antibody immunotherapy candidates focused on enhancing the innate and adaptive immune responses to enable a robust antitumor response and enhance outcomes for patients with cancer. Casdozokitug is a novel IL-27 antagonistic antibody currently being evaluated in a randomized Phase 2 study in patients with HCC. Tagmokitug (CHS-114) is a highly selective cytolytic anti-CCR8 antibody currently in Phase 1b/2a studies in patients with advanced solid tumors, including head and neck cancer, colorectal cancer, gastric cancer, and esophageal cancer.​Forward-Looking Statements​​​The statements in this press release include express or implied forward-looking statements within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995

    🔬 Clinical Development Pipeline (COHERUS ONCOLOGY, INC.):

    Product Type Development Stage Therapeutic Area Source
    CHS-114 Other Phase PHASE1 Advanced Solid Tumor ClinicalTrials.gov
    Casdozokitug Other Phase PHASE2 Hepatocellular Carcinoma ClinicalTrials.gov
    Toripalimab Other Phase PHASE1 Metastatic Colorectal Cancer ClinicalTrials.gov
    Dupilumab Other Phase PHASE1 Metastatic Colorectal Cancer ClinicalTrials.gov
    Carboplatin Other Phase PHASE4 Nasopharyngeal Cancer Recurrent ClinicalTrials.gov
    Gemcitabine Other Phase PHASE4 Nasopharyngeal Cancer Recurrent ClinicalTrials.gov
    Cisplatin Other Phase PHASE4 Nasopharyngeal Cancer Recurrent ClinicalTrials.gov
    STC-15 monotherapy Drug Phase PHASE1 Solid Tumor ClinicalTrials.gov
    STC-15 in combination with toripalimab Other Phase PHASE1 Solid Tumor ClinicalTrials.gov
    Pembrolizumab Other Phase PHASE1 Advanced Solid Tumor ClinicalTrials.gov
    CHS-388 Other Phase PHASE1 Advanced Solid Tumor ClinicalTrials.gov
    5 Fluorouracil Other Phase PHASE1 Metastatic Solid Tumor ClinicalTrials.gov
    Bevacizumab Other Phase PHASE2 Hepatocellular Carcinoma ClinicalTrials.gov
    Placebo Other Phase PHASE2 Hepatocellular Carcinoma ClinicalTrials.gov
    Atezolizumab Other Phase PHASE2 Hepatocellular Carcinoma ClinicalTrials.gov
    SRF388 Other Phase PHASE2 Hepatocellular Carcinoma ClinicalTrials.gov
    CHS-1000 Other Phase PHASE1 Advanced or Metastatic Solid Tumors ClinicalTrials.gov
    zimberelimab Other Phase PHASE2 Metastatic Castration-resistant Prostate Cancer ClinicalTrials.gov
    etrumadenant Other Phase PHASE2 Metastatic Castration-resistant Prostate Cancer ClinicalTrials.gov
    SRF617 Other Phase PHASE2 Metastatic Castration-resistant Prostate Cancer ClinicalTrials.gov
    Pegfilgrastim Other Phase PHASE1 Bioequivalence ClinicalTrials.gov
    CHS-1701 Other Phase PHASE1 Bioequivalence ClinicalTrials.gov
    Pegfilgrastim (Neulasta) Other Phase PHASE1 Immunity, Humoral ClinicalTrials.gov
    CHS-0214 Other Phase PHASE3 Rheumatoid Arthritis ClinicalTrials.gov
    Etanercept Other Phase PHASE3 Rheumatoid Arthritis ClinicalTrials.gov
    Adalimumab Other Phase PHASE3 Plaque Psoriasis ClinicalTrials.gov
    CHS-1420 Other Phase PHASE3 Plaque Psoriasis ClinicalTrials.gov
    Pegfilgrastim-Cbqv Other Preclinical Febrile Neutropenia ClinicalTrials.gov
    Albumin-Bound Paclitaxel Other Phase PHASE1 Advanced Solid Tumor ClinicalTrials.gov
    toripalimab (anti-PD-1) Other Phase PHASE1 Advanced Solid Tumor ClinicalTrials.gov
    CHS-006 (anti-TIGIT) Other Phase PHASE1 Advanced Solid Tumor ClinicalTrials.gov
    Radiation Therapy Drug Phase PHASE2 Sinonasal Cancer ClinicalTrials.gov
    Docetaxel Other Phase PHASE2 Sinonasal Cancer ClinicalTrials.gov
    Chemoradiotherapy or radiation Drug Phase PHASE2 Head and Neck Cancer ClinicalTrials.gov
    Toripalimab + Chemotherapy Drug Phase PHASE2 Head and Neck Cancer ClinicalTrials.gov
    Questionnaire Administration Other Phase PHASE2 Localized Colon Carcinoma ClinicalTrials.gov
    Computed Tomography Other Phase PHASE2 Localized Colon Carcinoma ClinicalTrials.gov
    Colonoscopy Other Phase PHASE2 Localized Colon Carcinoma ClinicalTrials.gov
    Biospecimen Collection Other Phase PHASE2 Localized Colon Carcinoma ClinicalTrials.gov
    Biopsy Procedure Procedure Phase PHASE2 Localized Colon Carcinoma ClinicalTrials.gov
    Toripalimab-tpzi Other Phase PHASE2 Squamous Cell Carcinoma ClinicalTrials.gov
    Nadunolimab Other Phase PHASE1 Metastatic Microsatellite Stable Colorectal Carcinoma ClinicalTrials.gov
    Paclitaxel Other Phase PHASE2 Head and Neck Squamous Cell Carcinoma (HNSCC) - Recurrent/Metastatic (R/M) ClinicalTrials.gov
    NY-ESO-1 Peptide vaccine BIOLOGICAL Phase PHASE2 Ovarian Cancer Stage IV ClinicalTrials.gov

    💼 Business Developments:

    • Partnership
    • Acquisition: Not available
    • Licensing
    • Regulatory Approval
    • Executive Changes: Not available

    Structured Data:

    • Company Name: COHERUS ONCOLOGY, INC.
    • Ticker Symbol: CHRS

Search

News categories